|
Market Closed -
Other stock markets
|
After hours 20:59:04 | |||
| 37.90 EUR | -0.92% |
|
37.42 | -1.25% |
| 12-10 | Dermapharm jumps high - founder Beier buys more shares | DP |
| 12-10 | Dermapharm founder Beier buys more shares | DP |
| Capitalization | 2.06B 2.4B 1.92B 1.79B 3.34B 217B 3.58B 22.06B 8.67B 104B 9.02B 8.83B 380B | P/E ratio 2025 * |
16.8x | P/E ratio 2026 * | 15.1x |
|---|---|---|---|---|---|
| Enterprise value | 2.88B 3.36B 2.68B 2.49B 4.66B 303B 5B 30.82B 12.12B 145B 12.6B 12.34B 531B | EV / Sales 2025 * |
2.45x | EV / Sales 2026 * | 2.27x |
| Free-Float |
32.26% | Yield 2025 * |
2.61% | Yield 2026 * | 2.86% |
| 1 day | -2.16% | ||
| 1 week | -1.04% | ||
| Current month | -3.68% | ||
| 1 month | +2.16% | ||
| 3 months | +15.90% | ||
| 6 months | +10.01% | ||
| Current year | -3.68% |
| 1 week | 37 |  | 40.55 |
| 1 month | 36.8 | | 40.55 |
| Current year | 37 | | 40.55 |
| 1 year | 31.7 | | 42.5 |
| 3 years | 30.15 | | 49.48 |
| 5 years | 30.15 | | 91.95 |
| 10 years | 21.58 | | 91.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2017 | |
| Director of Finance/CFO | - | 31/10/2022 | |
Britta Hamberger
IRC | Investor Relations Contact | - | 30/11/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Wilhelm Beier
CHM | Chairman | 69 | 31/07/2017 |
Erwin Kern
BRD | Director/Board Member | 65 | 31/07/2017 |
| Director/Board Member | 77 | 31/12/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 2.01% | 0 M€ | |
| -.--% | 0.16% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.92% | -1.04% | -5.25% | -4.44% | 2.4B | |
| +1.64% | +3.79% | +35.55% | +201.01% | 952B | |
| +2.61% | +2.65% | +45.17% | +20.53% | 492B | |
| -0.02% | -0.06% | +24.50% | +44.55% | 389B | |
| +0.50% | +5.22% | +29.29% | +18.53% | 363B | |
| -0.68% | +5.50% | +30.47% | +23.34% | 296B | |
| -1.21% | +1.63% | +8.13% | -2.31% | 274B | |
| -0.18% | +4.92% | +25.39% | +35.33% | 273B | |
| -0.62% | +9.33% | -38.17% | -17.02% | 264B | |
| -0.17% | +1.50% | +20.49% | +20.16% | 176B | |
| Average | +0.12% | +2.35% | +17.56% | +33.97% | 348.15B | |
| Weighted average by Cap. | +0.83% | +1.48% | +25.26% | +69.09% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.17B 1.37B 1.09B 1.02B 1.9B 124B 2.04B 12.59B 4.95B 59.16B 5.15B 5.04B 217B | 1.22B 1.43B 1.14B 1.06B 1.98B 129B 2.12B 13.08B 5.14B 61.48B 5.35B 5.24B 225B |
| Net income | 123M 143M 114M 106M 199M 12.92B 213M 1.32B 517M 6.18B 538M 527M 22.67B | 136M 159M 127M 118M 221M 14.33B 237M 1.46B 573M 6.86B 596M 584M 25.13B |
| Net Debt | 818M 955M 760M 709M 1.32B 86.06B 1.42B 8.76B 3.44B 41.17B 3.58B 3.51B 151B | 709M 828M 659M 615M 1.15B 74.61B 1.23B 7.59B 2.98B 35.69B 3.1B 3.04B 131B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/01/26 | 37.90 € | -0.92% | 14,023 |
| 09/01/26 | 38.25 € | -1.29% | 27,523 |
| 08/01/26 | 38.75 € | 0.00% | 30,308 |
| 07/01/26 | 38.75 € | -0.39% | 42,863 |
| 06/01/26 | 38.90 € | +1.57% | 69,611 |
Delayed Quote Xetra, January 12, 2026 at 04:39 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DMP Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition